Nonlinearity detection: advantages of nonlinear mixed-effects modeling

AAPS Journal

Volumn 2, Issue 3, 2000, Pages

  Niclas Jonsson, E ^a   Karlsson, Mats O ^b   Wade, Janet R ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Nonlinear mixedeffects modeling; Nonlinear pharmacokinetics and pharmacodynamics; Population analysis; Study design

Indexed keywords

EID: 52849124504     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ludden TM. Nonlinear pharmacokinetics. Clinical Implications. ClinPharmacokinet. 1991:20:429446.
2. Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? JPharmSci. 1996:85:232-239.
3. Spigset O. The selective serotonin reuptake inhibitor fluvoxamine. Ume university medical dissertations, 1997.
4. Blackledge GRP. High-dose bicalutamide monotherapy for the treatment of prostrate cancer. Urology 1996:47(suppl lA):44-47.
5. Sedman AJ, Wagner JG. Importance of Hie use of the appropriate pharmacokinetic model to analyse in vivo enzyme constants. J PharmacokinBiopharm. 1974:2:161-173.
6. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J PharmacokinBiopharm. 1977:5:445479.
7. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters, ii. Biexponential model and experimental pharmacokinetic data JPharmacokinBiopharm. 1981:9:635-651.
8. Graves DA, Chang I. Application of NONMEM to routine bioavailability data. JPharmacokinBiopharm. 1990:18:145-160.
9. Aarons O, Mandema JW, Danhof M. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat J Pharmacokin Biopharm. 1991:19:485496.
10. Beal SL, Sheiner LB. NONMEM Users Guides. NONMEM Project Group, University of California at San Francisco, 1992.
11. Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. B JClinPharmacol. 1996:42:283-290.
12. Hashimoto Y, Mori S, Hama N, Nakao K, Imura H, Yamaguchi M, Yasuhara M, Hori R. Nonlinear mixed effect modelling of the pharmacodynamics of natriuretic peptides in rats. J Pharmacokin Biopharm. 1993:21:281-297.
13. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, and Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994:17:323-326.
14. Hashimoto Y, Ozaki J, Koue T, Odani A, Yasuhara M, Hori R. Simulation for the analysis of distorted pharmacodynamic data Pharm Res. 1994:11:545-548.
15. Beal SL, Sheiner LB. NONMEM Users Guide - Part VII. Conditional estimation methods. University of California at San Francisco, November 1992.
16. Rodman JH, Silverstein K. Comparison the two stage (TS) and first order (FO) methods for estimation of population parameters in an intensive pharmacokinetic study. Clin Pharmacol Ther. 1990:47:151.
17. Godfrey KR, Fitch WR. The deterministic identifJabiliry of nonlinear pharmacokinetic models. J Pharmacokin Biopharm. 1984:12:177-191.
18. Godfrey KR, Fitch WR. On the identification of Michaelis-Menton elimination parameters from a single dose-response curve. J Pharmacokin Biopharm. 1984:12:193-221.
19. Godfrey KR, Chapman MJ, Vajda S. Identifiability and indistinguishability of nonlinear pharmacokinetic models. J Pharmacokin Biopharm. 1994:22:229-251.
20. Hashimoto Y, Koue T, Otsuki Y, Yasuhara M, Hori R, Inui K. Simulation for population analysis of Michaelis-Menton kinetics. J Pharmacokin Biopharm. 1995:23:205-216.